Unify CRT-D and Fortify ICD
Deborah is the first hospital in the region to implant new defibrillators, recently approved by the FDA, – the Unify CRT-D and the Fortify ICD – both manufactured by St. Jude Medical. An ICD is an implantable device that treats potentially lethal, abnormally fast heart rhythms which can lead to sudden cardiac death. The new devices hold the highest amount of energy found in any defibrillator, with the ability to deliver 40 joules and are specially designed to prevent unnecessary defibrillation. They are smaller in size allowing physicians to implant them using a smaller incision with subsequent less scarring.
Approximately five million Americans suffer from heart failure and about 325,000 die from sudden cardiac death each year. The new devices are major advances in improving electrical interface to correct heart rhythm.
A CRT-D device resyncs the beating of the heart’s lower chambers, which often beat out of sync in heart failure patients. CRT therapy can greatly improve the quality of life for patients suffering with heart failure.
The additional energy capability found in the smaller CRT-D and ICD devices are especially important for patients who have an enlarged heart, low ejection-fraction, advanced heart failure, or those who require a higher amount of energy to shock their hearts to a normal rhythm.
The new devices increase the possibilities of heart failure patients and those with abnormal heart rhythms to live a longer, better quality of life. These devices also improve patient comfort with less bulk, reducing the need for set screws and lead connections to the device.
ENERGEN CRT-D and ICD Device
The ENERGEN cardiac resynchronization therapy defibrillator (CRT-D) and implantable cardioverter defibrillator (ICD) is used to treat heart failure and sudden cardiac death. The system is designed to simplify and reduce the time needed for the implant procedure by combining three separate lead terminals into one integrated connector and reducing the number of connections and set screws needed in the device header. In addition, some patients will receive a remote monitoring system where an at-home communicator will allow physicians to monitor the patient’s device, as well as vital signs such as blood pressure and weight, in order to better manage this complex disease.
Use of the Impella LP 2.5 Heart Pump with the Stereotaxis Remote Navigation System for Treating V-Tach Ablations
Several cutting-edge technologies have been combined together to provide life-saving care for a patient with ventricular tachycardia (V-Tach) -- a life-threatening heart arrhythmia that originates in the bottom chambers of the heart and is often responsible for sudden cardiac arrest.
Deborah physicians have expanded its use of the Stereotaxis Remote Navigation System (which is able to provide a flexible, robotically-driven catheter ablation to delivers radiofrequency energy to destroy small areas of heart tissue responsible for the arrhythmia) in combination with the Impella LP 2.5 heart pump. This combined use allows ablation treatment for patients with advanced heart damage and progressive heart failure who were not previously considered for the Stereotaxis Magnetic Navigation System procedure, because V-Tach in the damaged heart is often too complex to safely treat with the lengthy ablation procedure is required for a successful outcome.
The use of the Impella LP 2.5 heart pump -- the world’s smallest heart pump -- provides the heart with active support in critical situations, pumping up to 2.5 liters of blood per minute -- flowing continuously from the left ventricle into the ascending aorta -- allowing for critically-needed intervention care.